Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* In female subjects either childbearing potential terminated by surgery or one year post-menopausal, or a negative serum pregnancy test during screening and the willingness not to become pregnant during the study period and 30 days after the last vaccination by practicing reliable methods of contraception~* Written informed consent obtained prior to study entry~Exclusion Criteria:~* History of clinical manifestation of any flavivirus infection~* History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue fever (an anti-JEV neutralizing antibody titer \>= 1:10 at baseline is acceptable for inclusion, these subjects will be part of the safety population, but will not be analyzed for immunogenicity in the per-protocol analysis)~* History of any previous Hepatitis A vaccination and infection~* Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine~* Planned administration of another vaccine during the study period~* Immunodeficiency including post-organ-transplantation or immunosuppressive therapy~* A family history of congenital or hereditary immunodeficiency~* History of autoimmune disease~* Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of vaccination.~* Any acute infections within 4 weeks prior to enrollment~* Infection with human immunodeficiency virus (HIV), Hepatitis B (HBsAg) or Hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- IC51 and Placebo (Type: ACTIVE_COMPARATOR): 6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)
- HAVRIX and placebo (Type: ACTIVE_COMPARATOR): HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)
- IC51 and HAVRIX (Type: ACTIVE_COMPARATOR): IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)

Based on this trial design, predict the completion outcome and termination type (if applicable).